Disease characteristics and FLT3/ITD detection in CD34+/CD33- and CD34+/CD33+ progenitors and their resultant CFU-GM and BFU-E colonies
. | Disease characteristics . | . | . | FLT3 status in CD34+/CD33- cells/colonies . | . | . | FLT3 status in CD34+/CD33+ cells/colonies . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | BM blasts, % . | CD34+/CD33- cell count, × 104 (% total) . | Allelic ratio . | Freshly sorted cells . | CFU-GM, n (%) . | BFU-E, n (%) . | Freshly sorted cells . | CFU-GM, n (%) . | BFU-E, n (%) . | ||||||
| 1* | 96 | 0.05 (0.005) | 0.2 | NA | 0/11 (0) | NG | ITD | NG | NG | ||||||
| 2* | 91 | 0.2 (0.01) | 0.19 | WT | 0/8 (0) | 0/2 (0) | ITD | 0/8 (0) | 0/4 (0) | ||||||
| 3* | 36 | 32 (4) | 0.12 | WT | 0/51 (0) | 0/16 (0) | ITD | 0/1 (0) | 0/1 (0) | ||||||
| 4* | 60 | 0.1 (0.01) | 0.29 | WT | 0/17 (0) | 0/2 (0) | ITD | NG | NG | ||||||
| 5* | 81 | 0.3 (0.006) | 0.52 | WT | 0/30 (0) | 0/12 (0) | ITD | 3/10 (30) | NG | ||||||
| 6 | 44 | 28 (1) | 0.56 | ITD | NG | NG | ITD | NG | NG | ||||||
| 7 | 68 | 0.08 (0.003) | 1.6 | ITD | 0/6 (0) | 0/5 (0) | ITD | 0/1 (0) | NG | ||||||
| 8 | 92 | 34 (2) | 0.8 | ITD | 0/5 (0) | NG | ITD | 0/1 (0) | 0/4 (0) | ||||||
| 9 | 41 | 15 (1) | 0.73 | ITD | 0/3 (0) | NG | ITD | NG | NG | ||||||
| 10 | 85 | 0.3 (0.03) | 0.76 | ITD | 1/47 (2) | 1/13 (8) | ITD | 0/3 (0) | 1/1 (100) | ||||||
| 11 | 59 | 0.08 (0.01) | 0.7 | ITD | 1/16 (6) | 0/4 (0) | ITD | 0/3 (0) | 0/1 (0) | ||||||
| 12 | 90 | 150 (16) | 0.48 | ITD | 1/17 (6) | 0/20 (0) | ITD | 0/1 (0) | 0/2 (0) | ||||||
| 13 | 85 | 1 (0.02) | 0.58 | ITD | 4/33 (12) | 0/21 (0) | NA | 9/10 (90) | 0/2 (0) | ||||||
| 14 | 66 | 7 (0.4) | 0.62 | ITD | 5/35 (14) | 0/12 (0) | ITD | 7/8 (88) | NG | ||||||
| 15 | 71 | 82 (8) | 0.18 | ITD | 3/19 (16) | 0/15 (0) | ITD | 3/3 (100) | 0/7 (0) | ||||||
| 16 | 48 | 10 (1) | 0.13 | ITD | 2/9 (22) | 0/5 (0) | ITD | 0/2 (0) | NG | ||||||
| 17 | 78 | 0.8 (0.08) | 2 | ITD | 15/56 (27) | 1/21 (5) | NA | 2/11 (18) | 1/1 (100) | ||||||
| 18 | 74 | 2 (0.2) | 0.53 | ITD | 11/19 (58) | 0/5 (0) | ITD | 2/6 (33) | NG | ||||||
| 19 | 70 | 8 (0.3) | 0.75 | ITD | 28/42 (67) | 0/10 (0) | NA | 12/15 (80) | NG | ||||||
| 20 | 88 | 3 (0.1) | 0.4 | ITD | 28/37 (76) | 0/9 (0) | ITD | 39/46 (85) | NG | ||||||
| 21 | 61 | 3 (0.4) | 0.6 | ITD | 7/9 (78) | NG | ITD | 12/12 (100) | NG | ||||||
| 22 | 89 | 17 (0.4) | 2.8 | ITD | 18/22 (82) | 9/9 (100) | ITD | 7/7 (100) | 7/7 (100) | ||||||
| 23 | 75 | 3 (0.3) | 0.62 | ITD | 19/22 (86) | 3/3 (100) | ITD | 4/4 (100) | NG | ||||||
| 24 | 93 | 2 (0.1) | 0.82 | ITD | 3/3 (100) | 1/1 (100) | ITD | 3/3 (100) | 4/4 (100) | ||||||
. | Disease characteristics . | . | . | FLT3 status in CD34+/CD33- cells/colonies . | . | . | FLT3 status in CD34+/CD33+ cells/colonies . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | BM blasts, % . | CD34+/CD33- cell count, × 104 (% total) . | Allelic ratio . | Freshly sorted cells . | CFU-GM, n (%) . | BFU-E, n (%) . | Freshly sorted cells . | CFU-GM, n (%) . | BFU-E, n (%) . | ||||||
| 1* | 96 | 0.05 (0.005) | 0.2 | NA | 0/11 (0) | NG | ITD | NG | NG | ||||||
| 2* | 91 | 0.2 (0.01) | 0.19 | WT | 0/8 (0) | 0/2 (0) | ITD | 0/8 (0) | 0/4 (0) | ||||||
| 3* | 36 | 32 (4) | 0.12 | WT | 0/51 (0) | 0/16 (0) | ITD | 0/1 (0) | 0/1 (0) | ||||||
| 4* | 60 | 0.1 (0.01) | 0.29 | WT | 0/17 (0) | 0/2 (0) | ITD | NG | NG | ||||||
| 5* | 81 | 0.3 (0.006) | 0.52 | WT | 0/30 (0) | 0/12 (0) | ITD | 3/10 (30) | NG | ||||||
| 6 | 44 | 28 (1) | 0.56 | ITD | NG | NG | ITD | NG | NG | ||||||
| 7 | 68 | 0.08 (0.003) | 1.6 | ITD | 0/6 (0) | 0/5 (0) | ITD | 0/1 (0) | NG | ||||||
| 8 | 92 | 34 (2) | 0.8 | ITD | 0/5 (0) | NG | ITD | 0/1 (0) | 0/4 (0) | ||||||
| 9 | 41 | 15 (1) | 0.73 | ITD | 0/3 (0) | NG | ITD | NG | NG | ||||||
| 10 | 85 | 0.3 (0.03) | 0.76 | ITD | 1/47 (2) | 1/13 (8) | ITD | 0/3 (0) | 1/1 (100) | ||||||
| 11 | 59 | 0.08 (0.01) | 0.7 | ITD | 1/16 (6) | 0/4 (0) | ITD | 0/3 (0) | 0/1 (0) | ||||||
| 12 | 90 | 150 (16) | 0.48 | ITD | 1/17 (6) | 0/20 (0) | ITD | 0/1 (0) | 0/2 (0) | ||||||
| 13 | 85 | 1 (0.02) | 0.58 | ITD | 4/33 (12) | 0/21 (0) | NA | 9/10 (90) | 0/2 (0) | ||||||
| 14 | 66 | 7 (0.4) | 0.62 | ITD | 5/35 (14) | 0/12 (0) | ITD | 7/8 (88) | NG | ||||||
| 15 | 71 | 82 (8) | 0.18 | ITD | 3/19 (16) | 0/15 (0) | ITD | 3/3 (100) | 0/7 (0) | ||||||
| 16 | 48 | 10 (1) | 0.13 | ITD | 2/9 (22) | 0/5 (0) | ITD | 0/2 (0) | NG | ||||||
| 17 | 78 | 0.8 (0.08) | 2 | ITD | 15/56 (27) | 1/21 (5) | NA | 2/11 (18) | 1/1 (100) | ||||||
| 18 | 74 | 2 (0.2) | 0.53 | ITD | 11/19 (58) | 0/5 (0) | ITD | 2/6 (33) | NG | ||||||
| 19 | 70 | 8 (0.3) | 0.75 | ITD | 28/42 (67) | 0/10 (0) | NA | 12/15 (80) | NG | ||||||
| 20 | 88 | 3 (0.1) | 0.4 | ITD | 28/37 (76) | 0/9 (0) | ITD | 39/46 (85) | NG | ||||||
| 21 | 61 | 3 (0.4) | 0.6 | ITD | 7/9 (78) | NG | ITD | 12/12 (100) | NG | ||||||
| 22 | 89 | 17 (0.4) | 2.8 | ITD | 18/22 (82) | 9/9 (100) | ITD | 7/7 (100) | 7/7 (100) | ||||||
| 23 | 75 | 3 (0.3) | 0.62 | ITD | 19/22 (86) | 3/3 (100) | ITD | 4/4 (100) | NG | ||||||
| 24 | 93 | 2 (0.1) | 0.82 | ITD | 3/3 (100) | 1/1 (100) | ITD | 3/3 (100) | 4/4 (100) | ||||||
BM indicates bone marrow; NA, not available; NG, no growth; ITD, FLT3/ITD-positive; WT, FLT3 wild type
Patients lacking FLT3/ITD detection in CD34+/CD33- progenitors